Aaron Tallent
Freelance Writer and Editor at Freelance
Writer with more than 20 years in communication fields including journalism, media advocacy, health, and sports history. Co-host of the @LoadedGoatPod.
Articles
-
4 days ago |
oncologynewscentral.com | Aaron Tallent
Chemotherapy‑induced thrombocytopenia (CIT) is a common adverse event (AE) that can negatively affect care. Now, results from the phase 3 RECITE trial show that romiplostim (Nplate) is effective in treating it in patients with a gastrointestinal (GI) cancer who are receiving oxaliplatin-based chemotherapy. Researchers presented the findings at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and say that the data offer a potential new option for managing CIT (Abstract 12007).
-
4 days ago |
oncologynewscentral.com | Aaron Tallent
Adjuvant cisplatin plus radiotherapy has been the standard of care for the last 20 years in patients with resected locally advanced head and neck squamous cell carcinoma (HNSCC) with a high risk for relapse.
-
5 days ago |
oncologynewscentral.com | Aaron Tallent
Adjuvant atezolizumab (Tecentriq) plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) reduced disease recurrence and death by 50% in patients with deficient DNA mismatch repair (dMMR) colon cancer when compared with adjuvant chemotherapy alone, according to results of the phase 3 ATOMIC trial.
-
5 days ago |
oncologynewscentral.com | Aaron Tallent
Neoadjuvant chemotherapy with gemcitabine (Gemzar) and cisplatin (Platinol), followed by radical liver resection, may improve overall survival (OS) in biliary tract cancer when compared with immediate radical liver resection alone and adjuvant therapy, according to final results from the shortened phase 3 GAIN trial, presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 4008).
-
2 weeks ago |
medcentral.com | Aaron Tallent
Idiopathic pulmonary fibrosis (IPF) is a challenging respiratory condition with limited treatment options. However, new therapies are being investigated, including one that was developed in part through generative artificial intelligence (AI). Research findings on rentosertib (INS018-055) were presented this week at the 2025 American Thoracic Society (ATS) annual meeting in San Franciso.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →Coverage map
X (formerly Twitter)
- Followers
- 1K
- Tweets
- 6K
- DMs Open
- No
Payer contract negotiations in #Oncology are all about relationships, timing, and data. 🤝 From term notices tousing deprivation scores for public-health insights, practice leaders at #COA2025 discuss their approach. #CancerCare https://t.co/KSZl4soPuW
Clinical trials are booming—2,000 new trials/year (+11% since 2019)—yet access at community oncology practices remains flat. 🚀 Success drivers? Physician champions, dedicated trial staff, and site management organizations! #COA2025 #CancerResearch https://t.co/yciF0PFkea
The upcoming #COA2025 Community Oncology Conference will include sessions on Medicare drug-price negotiations, leadership & team culture, and the future of AI in oncology workflows. #CommunityOncology #CancerCare https://t.co/c8klUB6QiO